Invivyd, Inc. (IVVD) stock
Close on Nov 12, 2026Market cap $167.22MP/E –Yield –
Invivyd, Inc. grew revenue 26.3% to $58.37M over the twelve months to Jun 30, 2026. Free cash flow was -$109.66M. At the latest close the market valued the company at $167.22M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $167.22M
- P/E ratio
- –
- Price to sales
- 2.87
- Price to book
- 0.92
- Dividend yield
- –
- Free cash flow yield
- -65.58%
Fundamentals
- Revenue
- $58.37M
- Net income
- -$107.33M
- EPS, diluted
- -$0.37
- Free cash flow
- -$109.66M
- Book value per share
- $0.57
- Diluted shares
- 320M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $0.60
- Open
- $0.59
- Day's range
- $0.55 – $0.60
- Volume
- 2,717,118
- Average volume (20 days)
- 3,863,805
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.41
- 52-week range
- $0.53 – $3.07
- RSI (14 days)
- 40.6
- Volatility (1 year)
- 108.9%
- Relative volume
- 0.59×
- WACC
- 11.9%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | IVVD | S&P 500 | Difference | IVVD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -15.7% | -2.7% | −13.0 pts | ||
| 3 months | -22.5% | -1.7% | −20.8 pts | ||
| Year to date | -77.0% | +11.9% | −88.9 pts | ||
| 1 year | -67.9% | +12.0% | −79.9 pts | ||
| 3 years | -59.5% | +78.2% | −137.7 pts | -26.0% | +21.2% |
| 5 years | -97.0% | +73.2% | −170.3 pts | -50.5% | +11.6% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Invivyd filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- Results
- News
- Results
About Invivyd
Biological Products, (No Diagnostic Substances)
Invivyd, Inc. is a biopharmaceutical company that discovers, develops, and commercializes monoclonal antibody therapies to prevent and treat serious viral infectious diseases. Its primary product is PEMGARDA, an authorized monoclonal antibody used as pre-exposure prophylaxis against COVID-19. The company also develops investigational candidates, including VYD2311 for COVID-19 and VBY329 for respiratory syncytial virus, alongside early research targeting measles. Its treatments serve vulnerable populations, specifically immunocompromised adults and adolescents who cannot generate an adequate immune response from vaccination, distributed through specialized healthcare practitioners in oncology, hematology, rheumatology, and transplantation.
Company profile, executives and historyInvivyd stock: common questions
What is Invivyd's stock price?
IVVD closed at $0.57 on Nov 12, 2026, down 5.34% on the day. Over the past 52 weeks it traded between $0.53 and $3.07.
What is Invivyd's market cap?
Invivyd was worth $167.22M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is IVVD's P/E ratio?
Invivyd lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.37), so it has no meaningful P/E ratio.
How much revenue does Invivyd make?
Invivyd reported revenue of $58.37M for the twelve months to Jun 30, 2026, up 26.3% from a year earlier.
Does Invivyd pay a dividend?
No. Invivyd has not paid a cash dividend over the last twelve months.
When does Invivyd report earnings next?
Invivyd's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has IVVD stock performed over the past year?
Including dividends, IVVD returned -67.9% over the past year, against +12.0% for the S&P 500.
How many IVVD shares are sold short?
36M shares were sold short at the latest FINRA report, 14.74% of the float, or 9.7 days of average trading volume.
Who are Invivyd's competitors?
Companies most similar to Invivyd by business, industry and size include CHRS, PTHS, GLUE, KYMR, PLX.
See a number that looks wrong?